Prediction of the 3D structure and dynamics of human DP G-protein coupled receptor bound to an agonist and an antagonist.
Prostanoids play important physiological roles in the cardiovascular and immune systems and in pain sensation in peripheral systems through their interactions with eight G-protein coupled receptors. These receptors are important drug targets, but development of subtype specific agonists and antagonists has been hampered by the lack of 3D structures for these receptors. We report here the 3D structure for the human DP G-protein coupled receptor (GPCR) predicted by the MembStruk computational method. To validate this structure, we use the HierDock computational method to predict the binding mode for the endogenous agonist (PGD2) to DP. Based on our structure, we predicted the binding of different antagonists and optimized them. We find that PGD2 binds vertically to DP in the TM1237 region with the alpha chain toward the extracellular (EC) region and the omega chain toward the middle of the membrane. This structure explains the selectivity of the DP receptor and the residues involved in the predicted binding site correlate very well with available mutation experiments on DP, IP, TP, FP, and EP subtypes. We report molecular dynamics of DP in explicit lipid and water and find that the binding of the PGD2 agonist leads to correlated rotations of helices of TM3 and TM7, whereas binding of antagonist leads to no such rotations. Thus, these motions may be related to the mechanism of activation.
Li
Youyong
Y
Materials and Process Simulation Center (MC 139-74), California Institute of Technology, Pasadena, California 91125, USA.
Zhu
Fangqiang
F
Vaidehi
Nagarajan
N
Goddard
William A
WA
Sheinerman
Felix
F
Reiling
Stephan
S
Morize
Isabelle
I
Mu
Lan
L
Harris
Keith
K
Ardati
Ali
A
Laoui
Abdelazize
A
D000595:Amino Acid Sequence; D001665:Binding Sites; D003198:Computer Simulation; D006801:Humans; D057927:Hydrophobic and Hydrophilic Interactions; D008055:Lipids / Q000737:chemistry; D008958:Models, Molecular; D008969:Molecular Sequence Data; D015230:Prostaglandin D2 / Q000737:chemistry / Q000378:metabolism; D011487:Protein Conformation; D011971:Receptors, Immunologic / Q000819:agonists / Q000037:antagonists & inhibitors / Q000737:chemistry* / Q000378:metabolism; D011982:Receptors, Prostaglandin / Q000819:agonists / Q000037:antagonists & inhibitors / Q000737:chemistry* / Q000378:metabolism; D013329:Structure-Activity Relationship; D013816:Thermodynamics; D014867:Water / Q000737:chemistry
D008055:Lipids; D011971:Receptors, Immunologic; D011982:Receptors, Prostaglandin; D014867:Water; D015230:Prostaglandin D2; C036293:prostaglandin D2 receptor
J Biol Chem. 1997 May 23;272(21):13475-8
9153190
Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2736-41
14981238
J Comput Chem. 2005 Jan 15;26(1):48-71
15529328
J Biol Chem. 2000 Aug 11;275(32):24294-303
10827082
Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):5982-7
11972040
Annu Rev Pharmacol Toxicol. 2001;41:661-90
11264472
Eur J Biochem. 2004 Jul;271(14):3006-16
15233797
Proc Natl Acad Sci U S A. 2006 Mar 28;103(13):4882-7
16551744
J Med Chem. 2004 Jan 1;47(1):56-71
14695820
Nat Chem Biol. 2006 Sep;2(9):467-73
16878128
Mol Pharmacol. 1999 Sep;56(3):545-51
10462542
Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3815-20
14999101
Biochem Biophys Res Commun. 1999 Feb 5;255(1):164-8
10082673
Nature. 1996 Sep 26;383(6598):347-50
8848049
J Biol Chem. 1997 Jun 13;272(24):15154-60
9182536
Proteins. 2003 Feb 1;50(2):213-21
12486715
Protein Sci. 2003 Sep;12(9):2001-14
12930999
Science. 2000 Aug 4;289(5480):739-45
10926528
Mol Pharmacol. 1998 Sep;54(3):584-90
9730918
Biophys J. 2004 Apr;86(4):1904-21
15041637
Biochem J. 2003 Apr 15;371(Pt 2):443-9
12519077
J Biol Chem. 1996 Mar 15;271(11):6233-40
8626415
Mol Pharmacol. 1997 Jan;51(1):61-8
9016347
J Biol Chem. 2006 Sep 15;281(37):27613-20
16837468
J Biol Chem. 2003 Feb 7;278(6):4250-7
12446735
Chem Senses. 2004 Sep;29(7):595-616
15337685
Mol Pharmacol. 2001 Jun;59(6):1446-56
11353805
Chem Senses. 2004 May;29(4):269-90
15150141
Science. 1996 Nov 1;274(5288):768-70
8864113
J Biol Chem. 2003 Mar 28;278(13):10922-7
12551898
Arch Biochem Biophys. 1996 Oct 1;334(1):9-17
8837733
Biochem J. 1995 Apr 15;307 ( Pt 2):493-8
7733888
Trends Pharmacol Sci. 2003 Feb;24(2):96-102
12559775
Mol Pharmacol. 1993 Nov;44(5):934-9
8246916
Annu Rev Pharmacol Toxicol. 2002;42:55-80
11807164
Physiol Rev. 1999 Oct;79(4):1193-226
10508233
ChemMedChem. 2006 Aug;1(8):878-90
16902941
Biochemistry. 2004 Jul 20;43(28):8974-86
15248755
Eur J Pharmacol. 1998 Sep 11;357(1):73-82
9788776
FEBS Lett. 1999 Jan 29;443(3):357-62
10025963
J Biol Chem. 1990 Mar 15;265(8):4240-6
2137820
J Mol Biol. 1990 Oct 5;215(3):403-10
2231712
Protein Eng Des Sel. 2006 May;19(5):195-203
16517553
Science. 2000 Mar 17;287(5460):2013-7
10720327
Protein Sci. 2004 Oct;13(10):2693-705
15388861